Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis
Heliac
1 other identifier
interventional
60
1 country
1
Brief Summary
The purpose of this study is to investigate the role of endotoxins and the endotoxin mediated immune activation pathway in patients with alcoholic hepatitis. Also, to determine the effect of Liver assist (liver dialyses) intervention on these parameters in patients with severe alcoholic hepatitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2009
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2009
CompletedFirst Submitted
Initial submission to the registry
October 8, 2009
CompletedFirst Posted
Study publicly available on registry
October 9, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedSeptember 15, 2011
September 1, 2011
2.1 years
October 8, 2009
September 14, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum endotoxin levels
one year
Secondary Outcomes (1)
Endotoxin activation pathway proteins
1 year
Study Arms (2)
albumin liver dialysis
EXPERIMENTALStandard medial care without dialysis
NO INTERVENTIONInterventions
6 hour dialysis for 3 consecutive days
Eligibility Criteria
You may qualify if:
- Patients with alcoholic hepatitis based on the following criteria
- Alcohol intake for 6 consecutive months above 40g /day, at admission or 3 months earlier.
- Serum bilirubin level above 80 mmol/l
- Liver biopsy when diagnosis is unclear.
You may not qualify if:
- Heart failure
- Pregnancy
- non fluent danish speakers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Medicine V, Aarhus University Hospital
Aarhus, 8000, Denmark
Related Publications (1)
Stoy S, Dige A, Sandahl TD, Laursen TL, Buus C, Hokland M, Vilstrup H. Cytotoxic T lymphocytes and natural killer cells display impaired cytotoxic functions and reduced activation in patients with alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol. 2015 Feb 15;308(4):G269-76. doi: 10.1152/ajpgi.00200.2014. Epub 2014 Dec 11.
PMID: 25501547DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Hendrik Vilstrup, Prof
Department of Medicine V, Aarhus University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
October 8, 2009
First Posted
October 9, 2009
Study Start
August 1, 2009
Primary Completion
September 1, 2011
Study Completion
September 1, 2011
Last Updated
September 15, 2011
Record last verified: 2011-09